X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with SUVEN LIFE - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs SUVEN LIFE - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES SUVEN LIFE ALKEM LABORATORIES/
SUVEN LIFE
 
P/E (TTM) x - 19.1 - View Chart
P/BV x 7.4 3.5 208.2% View Chart
Dividend Yield % 0.6 1.1 55.6%  

Financials

 ALKEM LABORATORIES   SUVEN LIFE
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
SUVEN LIFE
Mar-16
ALKEM LABORATORIES/
SUVEN LIFE
5-Yr Chart
Click to enlarge
High Rs1,589339 469.4%   
Low Rs1,232144 853.2%   
Sales per share (Unadj.) Rs417.539.2 1,063.7%  
Earnings per share (Unadj.) Rs56.37.5 754.5%  
Cash flow per share (Unadj.) Rs64.78.8 737.4%  
Dividends per share (Unadj.) Rs12.702.00 635.0%  
Dividend yield (eoy) %0.90.8 108.7%  
Book value per share (Unadj.) Rs292.949.0 597.9%  
Shares outstanding (eoy) m119.57127.28 93.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.46.2 54.9%   
Avg P/E ratio x25.132.4 77.4%  
P/CF ratio (eoy) x21.827.5 79.2%  
Price / Book Value ratio x4.84.9 97.7%  
Dividend payout %22.626.8 84.2%   
Avg Mkt Cap Rs m168,65330,732 548.8%   
No. of employees `000NA1.0 0.0%   
Total wages/salary Rs m9,171416 2,202.5%   
Avg. sales/employee Rs ThNM5,236.1-  
Avg. wages/employee Rs ThNM436.5-  
Avg. net profit/employee Rs ThNM995.5-  
INCOME DATA
Net Sales Rs m49,9154,995 999.3%  
Other income Rs m1,645194 850.2%   
Total revenues Rs m51,5615,189 993.7%   
Gross profit Rs m8,4821,233 688.2%  
Depreciation Rs m1,006167 601.6%   
Interest Rs m67154 1,237.3%   
Profit before tax Rs m8,4511,205 701.5%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,606255 629.8%   
Profit after tax Rs m6,731950 708.8%  
Gross profit margin %17.024.7 68.9%  
Effective tax rate %19.021.2 89.8%   
Net profit margin %13.519.0 70.9%  
BALANCE SHEET DATA
Current assets Rs m27,0624,986 542.7%   
Current liabilities Rs m15,3241,042 1,470.3%   
Net working cap to sales %23.579.0 29.8%  
Current ratio x1.84.8 36.9%  
Inventory Days Days6761 109.0%  
Debtors Days Days4139 105.5%  
Net fixed assets Rs m12,6103,126 403.4%   
Share capital Rs m239127 187.8%   
"Free" reserves Rs m34,4903,717 927.8%   
Net worth Rs m35,0276,236 561.6%   
Long term debt Rs m1,212432 280.3%   
Total assets Rs m54,3878,079 673.2%  
Interest coverage x13.623.2 58.6%   
Debt to equity ratio x00.1 49.9%  
Sales to assets ratio x0.90.6 148.4%   
Return on assets %13.612.4 109.5%  
Return on equity %19.215.2 126.2%  
Return on capital %24.918.9 131.7%  
Exports to sales %12.987.5 14.8%   
Imports to sales %3.112.2 25.2%   
Exports (fob) Rs m6,4614,371 147.8%   
Imports (cif) Rs m1,540611 252.2%   
Fx inflow Rs m6,5634,666 140.6%   
Fx outflow Rs m3,012942 319.7%   
Net fx Rs m3,5523,724 95.4%   
CASH FLOW
From Operations Rs m7,259922 787.3%  
From Investments Rs m1,864-619 -301.0%  
From Financial Activity Rs m-9,273-698 1,327.7%  
Net Cashflow Rs m-150-396 37.9%  

Share Holding

Indian Promoters % 66.9 63.4 105.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 0.0 -  
FIIs % 0.0 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 36.5 -  
Shareholders   68,381 37,287 183.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   ORCHID PHARMA LTD  CIPLA  ABBOTT INDIA  UNICHEM LAB  WYETH LTD  

Compare ALKEM LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Day Flat; Oil and Gas Stocks Lead Losses(Closing)

After opening the day in red, share markets in India witnessed negative trading activity throughout the day and ended the day on a weak note.

Related Views on News

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Feb 22, 2018 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 8-QTR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS